Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Latent Tuberculosis Infection (LTBI) Testing market report explains the definition, types, applications, major countries, and major players of the Latent Tuberculosis Infection (LTBI) Testing market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
BioMerieux
Agilent Technologies
Roche
Thermo Fisher Scientific
Becton Dickinson
Qiagen
Danaher
Abbott Laboratories
Eppendorf
Bio-Rad Laboratories
By Type:
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
Others
By End-User:
Household Contacts with Pulmonary TB
PLHIV
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Latent Tuberculosis Infection (LTBI) Testing Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Latent Tuberculosis Infection (LTBI) Testing Outlook to 2028- Original Forecasts
-
2.2 Latent Tuberculosis Infection (LTBI) Testing Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Latent Tuberculosis Infection (LTBI) Testing Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Latent Tuberculosis Infection (LTBI) Testing Market- Recent Developments
-
6.1 Latent Tuberculosis Infection (LTBI) Testing Market News and Developments
-
6.2 Latent Tuberculosis Infection (LTBI) Testing Market Deals Landscape
7 Latent Tuberculosis Infection (LTBI) Testing Raw Materials and Cost Structure Analysis
-
7.1 Latent Tuberculosis Infection (LTBI) Testing Key Raw Materials
-
7.2 Latent Tuberculosis Infection (LTBI) Testing Price Trend of Key Raw Materials
-
7.3 Latent Tuberculosis Infection (LTBI) Testing Key Suppliers of Raw Materials
-
7.4 Latent Tuberculosis Infection (LTBI) Testing Market Concentration Rate of Raw Materials
-
7.5 Latent Tuberculosis Infection (LTBI) Testing Cost Structure Analysis
-
7.5.1 Latent Tuberculosis Infection (LTBI) Testing Raw Materials Analysis
-
7.5.2 Latent Tuberculosis Infection (LTBI) Testing Labor Cost Analysis
-
7.5.3 Latent Tuberculosis Infection (LTBI) Testing Manufacturing Expenses Analysis
8 Global Latent Tuberculosis Infection (LTBI) Testing Import and Export Analysis (Top 10 Countries)
-
8.1 Global Latent Tuberculosis Infection (LTBI) Testing Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Latent Tuberculosis Infection (LTBI) Testing Export by Region (Top 10 Countries) (2017-2028)
9 Global Latent Tuberculosis Infection (LTBI) Testing Market Outlook by Types and Applications to 2022
-
9.1 Global Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Tuberculin Skin Test (TST) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Interferon Gamma Released Assay (IGRA) Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Household Contacts with Pulmonary TB Consumption and Growth Rate (2017-2022)
-
9.2.2 Global PLHIV Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Latent Tuberculosis Infection (LTBI) Testing Market Analysis and Outlook till 2022
-
10.1 Global Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.2.2 Canada Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.2.3 Mexico Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.2 UK Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.3 Spain Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.4 Belgium Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.5 France Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.6 Italy Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.7 Denmark Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.8 Finland Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.9 Norway Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.10 Sweden Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.11 Poland Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.12 Russia Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.3.13 Turkey Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.2 Japan Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.3 India Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.4 South Korea Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.5 Pakistan Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.6 Bangladesh Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.7 Indonesia Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.8 Thailand Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.9 Singapore Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.10 Malaysia Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.11 Philippines Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.4.12 Vietnam Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.5.2 Colombia Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.5.3 Chile Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.5.4 Argentina Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.5.5 Venezuela Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.5.6 Peru Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.5.7 Puerto Rico Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.5.8 Ecuador Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.6.2 Kuwait Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.6.3 Oman Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.6.4 Qatar Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.6.5 Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.6.6 United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.7.2 South Africa Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.7.3 Egypt Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.7.4 Algeria Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
-
10.8.2 New Zealand Latent Tuberculosis Infection (LTBI) Testing Consumption (2017-2022)
11 Global Latent Tuberculosis Infection (LTBI) Testing Competitive Analysis
-
11.1 BioMerieux
-
11.1.1 BioMerieux Company Details
-
11.1.2 BioMerieux Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 BioMerieux Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.1.4 BioMerieux Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Agilent Technologies
-
11.2.1 Agilent Technologies Company Details
-
11.2.2 Agilent Technologies Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Agilent Technologies Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.2.4 Agilent Technologies Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Roche
-
11.3.1 Roche Company Details
-
11.3.2 Roche Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Roche Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.3.4 Roche Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Thermo Fisher Scientific
-
11.4.1 Thermo Fisher Scientific Company Details
-
11.4.2 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.4.4 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Becton Dickinson
-
11.5.1 Becton Dickinson Company Details
-
11.5.2 Becton Dickinson Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Becton Dickinson Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.5.4 Becton Dickinson Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Qiagen
-
11.6.1 Qiagen Company Details
-
11.6.2 Qiagen Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Qiagen Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.6.4 Qiagen Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Danaher
-
11.7.1 Danaher Company Details
-
11.7.2 Danaher Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Danaher Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.7.4 Danaher Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Abbott Laboratories
-
11.8.1 Abbott Laboratories Company Details
-
11.8.2 Abbott Laboratories Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Abbott Laboratories Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.8.4 Abbott Laboratories Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Eppendorf
-
11.9.1 Eppendorf Company Details
-
11.9.2 Eppendorf Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Eppendorf Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.9.4 Eppendorf Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Bio-Rad Laboratories
-
11.10.1 Bio-Rad Laboratories Company Details
-
11.10.2 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
11.10.4 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Latent Tuberculosis Infection (LTBI) Testing Market Outlook by Types and Applications to 2028
-
12.1 Global Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Tuberculin Skin Test (TST) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Interferon Gamma Released Assay (IGRA) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Household Contacts with Pulmonary TB Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global PLHIV Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Latent Tuberculosis Infection (LTBI) Testing Market Analysis and Outlook to 2028
-
13.1 Global Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.2.2 Canada Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.2.3 Mexico Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.2 UK Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.3 Spain Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.4 Belgium Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.5 France Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.6 Italy Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.7 Denmark Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.8 Finland Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.9 Norway Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.10 Sweden Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.11 Poland Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.12 Russia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.3.13 Turkey Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.2 Japan Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.3 India Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.4 South Korea Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.8 Thailand Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.9 Singapore Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.11 Philippines Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.5.2 Colombia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.5.3 Chile Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.5.4 Argentina Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.5.6 Peru Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.6.3 Oman Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.6.4 Qatar Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.7.2 South Africa Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.7.3 Egypt Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.7.4 Algeria Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Latent Tuberculosis Infection (LTBI) Testing
-
Figure of Latent Tuberculosis Infection (LTBI) Testing Picture
-
Table Global Latent Tuberculosis Infection (LTBI) Testing Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Latent Tuberculosis Infection (LTBI) Testing Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Tuberculin Skin Test (TST) Consumption and Growth Rate (2017-2022)
-
Figure Global Interferon Gamma Released Assay (IGRA) Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Household Contacts with Pulmonary TB Consumption and Growth Rate (2017-2022)
-
Figure Global PLHIV Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Latent Tuberculosis Infection (LTBI) Testing Consumption by Country (2017-2022)
-
Table North America Latent Tuberculosis Infection (LTBI) Testing Consumption by Country (2017-2022)
-
Figure United States Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Canada Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Mexico Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Table Europe Latent Tuberculosis Infection (LTBI) Testing Consumption by Country (2017-2022)
-
Figure Germany Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure UK Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Spain Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Belgium Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure France Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Italy Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Denmark Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Finland Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Norway Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Sweden Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Poland Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Russia Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Turkey Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Table APAC Latent Tuberculosis Infection (LTBI) Testing Consumption by Country (2017-2022)
-
Figure China Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Japan Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure India Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure South Korea Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Thailand Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Singapore Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Philippines Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Table South America Latent Tuberculosis Infection (LTBI) Testing Consumption by Country (2017-2022)
-
Figure Brazil Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Colombia Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Chile Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Argentina Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Peru Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Table GCC Latent Tuberculosis Infection (LTBI) Testing Consumption by Country (2017-2022)
-
Figure Bahrain Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Oman Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Qatar Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Table Africa Latent Tuberculosis Infection (LTBI) Testing Consumption by Country (2017-2022)
-
Figure Nigeria Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure South Africa Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Egypt Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure Algeria Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Table Oceania Latent Tuberculosis Infection (LTBI) Testing Consumption by Country (2017-2022)
-
Figure Australia Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Latent Tuberculosis Infection (LTBI) Testing Consumption and Growth Rate (2017-2022)
-
Table BioMerieux Company Details
-
Table BioMerieux Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table BioMerieux Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table BioMerieux Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Table Agilent Technologies Company Details
-
Table Agilent Technologies Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table Agilent Technologies Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table Agilent Technologies Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Table Roche Company Details
-
Table Roche Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table Roche Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Table Thermo Fisher Scientific Company Details
-
Table Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Table Becton Dickinson Company Details
-
Table Becton Dickinson Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table Becton Dickinson Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table Becton Dickinson Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Table Qiagen Company Details
-
Table Qiagen Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table Qiagen Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table Qiagen Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Table Danaher Company Details
-
Table Danaher Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table Danaher Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table Danaher Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Table Abbott Laboratories Company Details
-
Table Abbott Laboratories Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Laboratories Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table Abbott Laboratories Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Table Eppendorf Company Details
-
Table Eppendorf Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eppendorf Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table Eppendorf Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Table Bio-Rad Laboratories Company Details
-
Table Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Main Business and Markets Served
-
Table Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
-
Figure Global Tuberculin Skin Test (TST) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Interferon Gamma Released Assay (IGRA) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Household Contacts with Pulmonary TB Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global PLHIV Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast by Country (2022-2028)
-
Table North America Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast by Country (2022-2028)
-
Figure United States Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast by Country (2022-2028)
-
Figure Germany Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast by Country (2022-2028)
-
Figure China Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast by Country (2022-2028)
-
Figure Brazil Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast by Country (2022-2028)
-
Figure Australia Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Latent Tuberculosis Infection (LTBI) Testing Consumption Forecast and Growth Rate (2022-2028)
-
